FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment

US11447553B2 · kind B2 · utility

Inventors

• Kristen Pierce · Burlingame, US
• Janine Powers · Alameda, US
• Servando Palencia · San Francisco, US
• Robert Sikorski · Woodside, US
• Majid Ghoddusi · Walnut Creek, US
• Kartik KRISHNAN · South San Francisco, US

Key dates

• Filing date: Nov 22, 2016
• Grant date: Sep 20, 2022
• Expiry date: Nov 22, 2036

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.